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Abstract
Metabotrophic glutamate receptors (mGluRs) modulate cellular activities involved in the processes
of differentiation and degeneration. In this study, we have analysed the expression pattern of group-
I metabotropic glutamate receptor (mGlu-5) in cerebral cortex, corpus striatum, brainstem and
hippocampus of streptozotocin induced and insulin treated diabetic rats (D+I) as a function of age.
Also, the functional role of glutamate receptors in intra cellular calcium release from the pancreatic
islets was studied in vitro. The gene expression studies showed that mGlu-5 mRNA in the cerebral
cortex increased siginficantly in 7 weeks old diabetic rats whereas decreased expression was
observed in brainstem, corpus striatum and hippocampus when compared to control. 90 weeks old
diabetic rats showed decreased expression in cerebral cortex, corpus striatum and hippocampus
whereas in brainstem the expression increased significantly compared to their respective controls.
In 7 weeks old D+I group, mGlu-5 mRNA expression was significantly decreased in cerebral cortex
and corpus striatum whereas the expression increased significantly in brainstem and hippocampus.
90 weeks old D+I group showed an increased expression in cerebral cortex, while it was decreased
significantly in corpus striatum, brainstem and hippocampus compared to their respective controls.
In vitro studies showed that glutamate at lower concentration (10-7 M) stimulated calcium release
from the pancreatic islets. Our results suggest that mGlu-5 receptors have differential expression
in brain regions of diabetes and D+I groups as a function of age. This will have clinical significance
in management of degeneration in brain function and memory enhancement through glutamate
receptors. Also, the regulatory role of glutamate receptors in calcium release has immense
therapeutic application in insulin secretion and function.
Introduction
Glutamate is the major excitatory neurotransmitter in the
central nervous system and exerts its action through iono-
tropic (iGluRs) and metabotropic receptors (mGluRs).
mGluRs interact with iGluRs, ion channels and mem-
brane enzymes that modulates cellular activities involved
in the processes of differentiation and degeneration [1].
mGluRs have been divided into three subclasses accord-
ing to the second-messenger pathways activated and their
pharmacologic properties [2,3]. mGluR1 receptors are
involved in the processing of somatosensory information
as they are expressed in the thalamic neurons that receive
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direct sensory input [4]. Activation of group I receptors
(mGluR1 and -5) results in an increase in intracellular cal-
cium through a phospholipase C-inositoltriphosphate
pathway [5] and inhibits potassium currents. The factors
that modulate or disrupt IP3-mediated Ca2+  signaling
exert functional regulatory role in age related and other
neurodegenerative disorders [6-8].
Diabetes mellitus is an endocrine disorder of carbohy-
drate metabolism resulting primarily from inadequate
insulin release (Type I insulin-dependent diabetes melli-
tus) or insulin insensitivity coupled with inadequate com-
pensatory insulin release (Type II non-insulin-dependent
diabetes mellitus). Diabetes is associated with peripheral
as well as central nervous system neuropathy [9,10]. Age
related changes in the capacity of β-cell for proliferation
affect the insulin production and contribute to a decrease
in glucose tolerance with advance in age [11]. The excita-
tory amino acids, glutamate are pivotal elements in the
hypothalamic circuitry involved in the control of pituitary
function. Our previous studies reported an enhanced
glutamate dehydrogenase activity during diabetes [12,13]
and its regulation on brain glutamate toxicity [14]. Recent
evidence suggests that metabotropic glutamate receptors
are involved in the regulation of hormone secretion in the
endocrine pancreas. The endogenous activation of group-
I metabotropic glutamate receptors (mGlu5) are reported
to be important for an optimal insulin response to glucose
[15]. The functional and biochemical studies show that
long-term exposure to hyperglycaemia in STZ-induced
diabetic rats is associated with glutamate receptor abnor-
malities [16,17]. Increased glutamate content is reported
to cause neuronal degeneration [18-20]. Glutamate which
causes excitotoxic neuronal damage, increases calcium
influx through N-methyl-D-aspartate receptors in post
synaptic neurons, leading to phospholipase A2 mediated
arachidonic acid release and neuronal injury by inhibiting
the sodium ion channels [21]. mGluRs modulate several
G-protein-related signal transduction pathways including
intracellular calcium (iCa2+) that control neuronal devel-
opment [22]. The synaptic activation of presynaptic
Group I mGluRs increase intracellular Ca2+  and an
enhancement of spontaneous transmitter release [23].
Also, the role of group I and II (mGluRs) in mediating
Ca2+ oscillations was reported in astrocytes in situ [24]. In
the present study, we have investigated the gene expres-
sion of group I glutamate receptors (mGluR-5), in differ-
ent brain regions of streptozotocin induced diabetic rats
as a function of age. Also, the functional role of glutamate
receptors in intracellular calcium release from pancreatic
islets was studied in vitro.
Glutamate is essential for synaptic communication in the
CNS, but inadequate regulation of extracellular glutamate
and glutamate receptor agonists can cause toxicity in the
nervous system [25-27] leading to neurodegenerative dis-
orders. Acute or chronic diabetes leads to neurological
dysfunction and injury. Group I mGluRs are positively
coupled to phosphoinositide hydrolysis and the mobili-
zation of intracellular Calcium leading to excitotoxic cell
death. Metabotropic glutamate (mGlu) regulates synaptic
glutamate release both in vitro [28] rat brain slices [29]
and in vivo [30]. The role of mGluR5 receptors in diabetes
brain damage is not reported before. Our present studies
on mGluR5 receptor gene expressions will definitely
enlighten the involvement of glutamate in diabetes.
Materials and methods
Animals
Wistar weanling rats of 7-9 weeks old and 90-100 weeks
old purchased from Amrita Institute of Medical Sciences,
Cochin and Kerala Agricultural University, Mannuthy
were used for all experiments. They were housed in sepa-
rate cages under 12 hours light and 12 hours dark periods
and were maintained on standard food pellets and water
ad libitum. All animal care and procedures were in accord-
ance with the CPCSEA and National Institute of Health
guidelines.
Diabetes Induction
Animals were divided into the following groups as i) Con-
trol ii) Diabetic iii) Insulin treated diabetics (D+I) of 7
weeks old and 90 weeks old rats. Each group consisted of
4-6 animals. Diabetes was induced by a single intrafemo-
ral dose [50-60 mg/kg body weight) of streptozotocin
(Sigma chemicals Co., St. Louis, MO, U.S.A.) freshly pre-
pared in citrate buffer, pH 4.5 under anesthesia [31-33].
The control rats were given the citrate buffer injection. The
insulin treated diabetic group received a daily dose (1
Unit/kg body weight) of Lente and Plain insulin (Abbott
India). The dose was increased daily according to the
blood glucose level [34]. Blood glucose was estimated by
glucose-oxidase peroxidase method using Glucose estima-
tion kit (Merck).
Sacrifice and tissue preparation
The animals were then sacrificed on 15th day by decapita-
tion. The brain regions were dissected out quickly over ice
according to the procedure of Glowinski and Iversen,
[35]. The tissues were stored at -70°C until assay.
Analysis of gene expression by Real-Time PCR
Total RNA was isolated from the brain regions of control
and experimental rats using Tri reagent. RNA was reverse
transcribed using ABI PRISM cDNA Archive kit. 20 μl of
the reaction mixture contained 0.2 μg total RNA, 10× RT
buffer, 25× dNTP mixture, 10× Random primers, Multi-
Scribe RT (50 U/μl) and RNase free water. The reactions
were carried out at 25°C for 10 minutes and 37°C for 2
hours using an Eppendorf Personal Cycler. Real-Time PCRJournal of Biomedical Science 2009, 16:99 http://www.jbiomedsci.com/content/16/1/99
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assays were performed using specific primer and fluores-
cently labeled Taq probe in an ABI 7300 Real-Time PCR
instrument (Applied Biosystems). The TaqMan reaction
mixture of 20 μl contained 25 ng of total RNA-derived
cDNAs, 200 nM each of the forward primer, reverse
primer and TaqMan probe for mGlu-5 gene, endogenous
control, β-actin and 12.5 μl of TaqMan 2× Universal PCR
Mastermix. The thermocycling profile conditions used
were: 50°C - 2 minutes - Activation; 95°C - 10 minutes -
Initial Denaturation; followed by 40 cycles of 95°C - 15
seconds - Denaturation and 60°C-1 minute - Annealing.
The ΔΔCT method of relative quantification was used to
determine the fold change in expression. This was done by
first normalizing the resulting threshold cycle (CT) values
of the target mRNAs to the CT values of the internal con-
trol β-actin in the same samples (ΔCT = CTTarget - CTβ-actin).
It was further normalized with the control (ΔΔCT = ΔCT -
CTControl). The fold change in expression was then
obtained as (2-ΔΔCT) and expressed as log 2-ΔΔCT.
Primer Sequence
Beta actin: TCA CCC ACA CTG TGC CCC ATC TAC GA
mGlu-5 receptor: TTCTGGGCAGTGATGGCTGGGCCGA
Isolation of pancreatic islets
Pancreatic islets were isolated from 20 weeks old adult
Wistar rats by standard collagenase digestion procedures
using aseptic techniques [36]. The islets were isolated in
HEPES-buffered sodium free Hanks Balanced Salt Solu-
tion (HBSS) [37] with the following composition: 137
mM Choline chloride, 5.4 mM KCl, 1.8 mM CaCl2, 0.8
mM MgSO4, 1 mM KH2PO4, 14.3 mM KHCO3 and 10 mM
HEPES. Autoclaved triple distilled water was used in the
preparation of the buffer. The pancreas from both young
and old rats was aseptically dissected out into a sterile
petridish containing ice cold HBSS and excess fat and
blood vessels were removed. The pancreas was cut into
small pieces and transferred to a sterile glass vial contain-
ing 2 ml collagenase type XI solution (1.5 mg/ml in HBSS,
pH 7.4). The collagenase digestion was carried out for 15
minutes at 37°C in an environmental shaker with vigor-
ous shaking (300 rpm/minute). The tissue digest was fil-
tered through 500 μm nylon screen and the filtrate was
washed with three successive centrifugations and resus-
pensions in cold HBSS. The pancreatic islet preparation
having a viability of >90% as assessed by Trypan Blue
exclusion which was chosen for cell culture and other
experiments.
Calcium imaging
Pancreatic islets were prepared from 20 weeks old adult
Wistar rats by collagenase digestion method as mentioned
earlier. The isolated islets were incubated for 4 hours at
room temperature in 1 ml of RPMI medium containing 5
μM of Ca2+ fluorescent dye, fluo 4-AM (Molecular Probes,
Eugene, OR), to monitor the changes in the intracellular
Ca2+. After incubation cells were washed twice in indicator
free RPMI medium to remove excess dye that was non-
specifically associated with the cell surface, and then incu-
bated for further 30 minutes to allow complete de esteri-
fication of intra cellular AM esters. The 35 mm plates,
containing pancreatic islet cells were placed on the stage
of a Leica TCS SP5 laser scanning confocal microscope
equipped with a HC PL FLUOTAR 20.0 × 0.50 dry objec-
tive (NA 0.5). Fluo 4-AM was excited with 514 nm laser
lines from an argon laser, with laser intensity set at 38%
of available power. For visualization of Fluo 4-AM, the
emission window was set at 508.4 nm - 571.5 nm. The
images were continuously acquired before and after addi-
tion of both higher (10-4 M) and lower concentration (10-
7 M) of glutamate, at time intervals of 1.318 seconds, for a
total of 600 seconds. Time series experiments were per-
formed collecting 512 × 512 pixel images at 400 Hz. Flu-
orescence intensity was analysed using the quantitation
mode in LAS-AF software from Leica Microsystems, Ger-
many. A region of interest (ROI) was drawn within a field
of view. For each ROI, the pixel intensity was calculated
for each image in the 600 seconds sequence to analyse the
intracellular Ca2+ release from the pancreatic islet cells in
experimental conditions.
Statistics
Statistical evaluations were performed by Student's t-Test
and ANOVA by using Graphpad InStat (Ver.2.04a, San
Diego, USA) computer program. Relative Quantification
Software was used for analyzing Real-Time PCR results.
Results
The body weight was significantly decreased (p < 0.001)
in 7 weeks old and 90 weeks old diabetic rat groups when
compared to their respective controls. After insulin treat-
ment for 14 days, the body weight was reversed to near the
initial level in both groups (Table 1, 2). Blood glucose
level of all rats before streptozotocin administration was
within the normal range. Streptozotocin administration
led to a significant increase (p < 0.001) in blood glucose
level of 7 weeks old and 90 weeks old diabetic rat groups
when compared to their respective controls. In both
groups, insulin treatment significantly reduce (p < 0.001)
the increased blood glucose level to near the control value
when compared to diabetic group (Table 3, 4).
The gene expression studies using Real-Time PCR showed
that the glutamate receptor (mGlu-5) mRNA in the cere-
bral cortex was increased siginficantly (p < 0.001) in 7
weeks old diabetic rats whereas decreased expression (p <
0.001) was observed in D+I group compared to control.
90 weeks old diabetic rats showed decreased expression (p
< 0.001) while D+I group showed an increased expressionJournal of Biomedical Science 2009, 16:99 http://www.jbiomedsci.com/content/16/1/99
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(p < 0.001) compared to control. Also, the expression was
decreased significantly in 90 weeks old diabetic rats (p <
0.001) whereas an increased expression pattern (p <
0.001) was observed in D+I groups compared to 7 weeks
old diabetic and D+I groups respectively (Fig 1).
In the corpus striatum, the gene expression decreased sig-
nificantly (p < 0.001) in 7 weeks and 90 weeks old dia-
betic and D+I groups when compared to control. In 90
weeks old diabetic group, we observed a decreased expres-
sion (p < 0.001) whereas D+I group showed an increased
expression (p < 0.001) compared to 7 weeks old diabetic
and D+I groups respectively (Fig 2). In the brainstem,
mGlu-5 mRNA expression was significantly decreased (p
< 0.001) in 7 weeks old diabetic whereas it was signifi-
cantly increased (p < 0.001) in D+I groups compared to
control. 90 weeks old diabetic rats showed an increased
expression while D+I group showed a decreased expres-
sion (p < 0.001) compared to control. Also, an increased
expression of mGlu-5 receptor mRNA was observed in 90
weeks old diabetic (p < 0.001) whereas D+I groups
showed decreased expression (p < 0.001) compared to 7
weeks old diabetic and D+I groups respectively (Fig 3).
The hippocampus elicit an increased mGlu-5 receptor
mRNA expression (p < 0.001) in 7 weeks old D+I groups
whereas it was significantly decreased (p < 0.001) in 7
weeks diabetic and 90 weeks old rat groups compared to
their respective controls. Also, a significant decrease in the
expression was observed in 90 weeks old diabetic (p <
0.001) and D+I (p < 0.001) groups compared to 7 weeks
old diabetic and D+I groups respectively (Fig 4).
In vitro studies showed that glutamate at 10-7 M signifi-
cantly increased Ca2+ release from the pancreatic islets (Fig
5, 6).
Discussion
Glutamate is an excitatory neurotransmitter in the mam-
malian central nervous system and mediates neurotrans-
mission across most excitatory synapses. Metabotrophic
glutamate receptors (mGluRs) are mainly found in pre
and postsynaptic neurons in synapses of the hippocam-
pus, cerebellum and the cerebral cortex as well as other
parts of the brain and in peripheral tissues. Previous
reports suggest the in adult rats mGluR-5 is expressed in
many brain regions highest in striatum, hippocampus
frontal cortex and relatively low in cerebellum and pons
medulla [38,39]. mGluR-5 receptors expression is pre-
cisely and complexly controlled at the level of transcrip-
tion and that different functions of mGlu5 during
different developmental periods and in distinct regions
are likely mediated by different splice variants [40].
The progression of diabetes is associated with an impaired
ability of the neurons in the CNS to release neurotrans-
mitters resulting in behavioral changes [41]. Among
them, the neurotransmitter receptor NMDA showed age-
related reduction of expression [42]. The cerebral cortex is
the seat of our highest forms of intelligence. It plays a cen-
tral role in many complex brain functions including
memory, attention, perceptual awareness, thought, lan-
guage, and consciousness. Glutamate triggers neuronal
death when released in excessive concentrations by over-
excitation of its receptors [43]. Age-related neuronal dys-
function causes a decline in cognitive function and other
subtle changes within the cortex including alterations in
receptors, loss of dendrites, and spines and myelin dystro-
phy, as well as the alterations in synaptic transmission
[44]. Glutamate receptor subtypes are critical in gating the
plasticity and memory formation. Also, learning and
memory deficits are associated with Type I and Type II dia-
betes mellitus [45] and brain morphological abnormali-
Table 1: Body weight (g) of Experimental rats (7 weeks old)
Animal status Initial 7th day 14th day
Control 110.0 ± 10.0 120.5 ± 12.0 133.3 ± 14.5
Diabetic 120.0 ± 5.7 86.6 ± 4.6 75.7 ± 3.6*** ϕϕϕ
Insulin treated Diabetic 116.6 ± 3.4 98.2 ± 2.0 106.6 ± 5.3¶¶¶
Values are mean ± S.E.M of 4-6 rats in each group.
***p < 0.001 when compared with control, ϕϕϕp < 0.001 when compared with initial weight, ¶¶¶p < 0.001 when compared with diabetic group.
Table 2: Body weight (g) of Experimental rats (90 weeks old)
Animal status Initial 7th day 14th day
Control 320.0 ± 12.0 325.0 ± 14.3 330.0 ± 15.0
Diabetic 360.0 ± 16.5 280.2 ± 3.3 250.7 ± 2.3*** ϕϕϕ
Insulin treated Diabetic 350.0 ± 13.3 300.6 ± 5.0 310.0 ± 5.8¶¶¶
Values are mean ± S.E.M of 4-6 rats in each group.
***p < 0.001 when compared with control, ϕϕϕp < 0.001 when compared with initial weight, ¶¶¶p < 0.001 when compared with diabetic group.Journal of Biomedical Science 2009, 16:99 http://www.jbiomedsci.com/content/16/1/99
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ties have been found in diabetic patients, mainly in the
cortex area [46]. Studies on streptozotocin (STZ)-induced
diabetic rat models have shown similar results which
exhibits morphological, behavioural and electrophysio-
logical alterations on diabetes [47-49]. Increased blood
glucose and decreased body weight observed during dia-
betes is similar with previous reports as a result of the
marked destruction of insulin secreting pancreatic islet β-
cells by streptozotocin [50]. During diabetes there is a
decrease in body weight as a result of altered metabolic
function. Insulin treatment normalised the increased
blood glucose level and decreased body weight to control
values.
Abnormal expression of glutamate receptor is also
involved in the development of diabetic neuropathy [51].
The brain regions - cerebral cortex and hippocampus of
diabetic rats is suggested to be more vulnerable to gluta-
mate toxicity via NMDA receptor activation. An Age-
related increase in group-I mGlu receptor mRNA levels
was found in thalamic nuclei, hippocampal CA3 with par-
allel increases in mGlu receptor protein expression [52].
Diabetes mellitus induces cognitive impairment and
defects of long-term potentiation (LTP) in the hippocam-
pus. From the gene expression studies, it is clear that in
cerebral cortex, mGlu-5 mRNA increased siginficantly in 7
weeks old diabetic rats compared to control groups. Aging
process affects NMDA receptors more in the intermediate
hippocampus than the dorsal [53]. The dysfunction in
hippocampal LTP, an electrophysiological model of syn-
aptic plasticity thought to subserve learning and memory
processes is associated with diabetic conditions [54,55].
Also, L- [(3)H]glutamate-labeled NMDA receptors were
found to be down regulated in primary sensory cortical
regions [56]. Brain stem is an important part of the brain
in monitoring the glucose status and the regulation of
feeding [57]. The dorsal motor nucleus of the vagus nerve
is located in the brainstem. It is connected to the endo-
crine pancreas exclusively via vagal fibres and has a role in
neurally mediated insulin release. Hippocampus is based
on recent or declarative memory and plays important
roles in long-term memory and spatial navigation. In
brainstem, corpus striatum and hippocampus, we
observed a decreased expression of mGlu-5 mRNA when
compared to control groups. 90 weeks old diabetic rats
showed decreased expression in cerebral cortex, corpus
striatum and hippocampus whereas in the brainstem the
expression increased significantly. Corpus striatum is best
known for its role in the planning and modulation move-
ment pathways but also involved in a variety of cognitive
process involving executive function. Studies show an age-
dependent reduction in the functional response of striatal
group I mGlu receptors, which may be one of the factors
underlying the reduced ability of aged striatum to inte-
grate information [58]. Our results suggest that glutamate
receptor alterations found in the brain regions contribute
to cognitive and memory deficits during diabetes as a
function of age.
Studies have shown that regulation of glutamate receptor
properties can contribute to learning and memory [59].
Activation of this neurotransmitter system is also involved
Table 3: Blood glucose (mg/dL) level in Experimental rats (7 weeks old)
Animal status 0 day
(Before STZ injection)
3rd day (Initial) 6th day 10th day 14th day (Final)
Control 108.6 ± 1.7 113.1 ± 0.8 120.5 ± 1.5 123.7 ± 0.7 127.5 ± 0.9
Diabetic 105.9 ± 0.7 256.2 ± 0.4 301.2 ± 0.5 305.7 ± 0.7 306.9 ± 1.3***
D + I 113.5 ± 1.2 258.8 ± 0.3 298.4 ± 0.9 182.8 ± 1.3 130.0 ± 1.1¶¶¶ ϕϕϕ
Values are mean ± S.E.M of 4-6 rats in each group.
*** P < 0.001 when compared to control, ¶¶¶P < 0.001 when compared to diabetic group,
ϕϕϕp < 0.001 when compared with initial reading.
D + I- Insulin treated Diabetic
Table 4: Blood glucose (mg/dL) level in Experimental rats (90 weeks old)
Animal status 0 day
(Before STZ injection)
3rd day (Initial) 6th day 10th day 14th day (Final)
Control 110.1 ± 1.5 120.2 ± 1.7 122.5 ± 0.6 127.9 ± 2.1 128.3 ± 1.21
Diabetic 115.7 ± 1.2 248.9 ± 1.5 260.5 ± 0.7 265.7 ± 0.4 267.9 ± 1.2***
D + I 119.2 ± 0.7 254.8 ± 0.6 262.4 ± 0.9 193.8 ± 1.2 164.6 ± 0.9¶¶¶ ϕϕϕ
Values are mean ± S.E.M of 4-6 rats in each group.
***P < 0.001 when compared to control, ¶¶¶P < 0.001 when compared to diabetic group,
ϕϕϕp < 0.001 when compared with initial reading.
D + I- Insulin treated DiabeticJournal of Biomedical Science 2009, 16:99 http://www.jbiomedsci.com/content/16/1/99
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in neurodegeneration following a wide range of neurolog-
ical insults, including ischemia, trauma and epileptic sei-
zures [60,61]. In rodents, N-methyl-D-aspartate (NMDA)
and non-NMDA receptors are two families of ionotropic
receptors stimulated by glutamate that have been impli-
cated in neurodegeneration [62]. Overactivation of these
receptors can cause cell damage by increasing intracellular
calcium concentration in neurons, thereby leading to the
generation of free radicals and activation of proteases,
phospholipases and endonucleases [63,64] as well as
transcriptional activation of specific cell death programs
[65].
In 7 weeks old D+I group, mGlu-5 mRNA expression was
significantly decreased in cerebral cortex and corpus stria-
tum whereas the expression increased significantly in
brainstem and hippocampus. 90 weeks old D+I group
showed an increased expression in cerebral cortex, while
it was decreased significantly in corpus striatum, brain-
stem and hippocampus compared to their respective con-
trols. Insulin is reported to regulate the reuptake of
catecholamine transporters. Intracerebroventricular injec-
tion of insulin is reported to cause an increased mRNA
expression of dopamine transporters [66]. Short-term
insulin treatment was found to alter NMDA receptor acti-
vation [67] as well as to interact with AMPA receptor traf-
ficking between the plasma membrane and the
intracellular compartment in neuronal cell culture [68]
indicating that mechanisms underlying diabetic neuropa-
thies could be initiated in the early stages of the disease, as
a consequence of abnormal glutamate receptor properties.
This is relevant to the clinical situation because excessive
activation of glutamate receptors is a characteristic feature
of brain damage during stroke and ischaemia [69], condi-
tions that are exacerbated by hyperglycaemic states.
Intracellular Ca2+ plays a major role in the physiological
responses of excitable cells and excessive accumulation of
internal Ca2+ is a key determinant of cell injury and death
[70]. Pancreatic islet cells express receptors and transport-
Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Cerebral cortex of Control, Diabetic and Insu- lin treated Diabetic Rats Figure 1
Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Cerebral cortex of Control, 
Diabetic and Insulin treated Diabetic Rats. Sample Names. 1. 7 weeks Control, 2. 7 weeks Diabetic, 3. 7 weeks Insulin 
treated Diabetic. 4. 90 weeks Control, 5. 90 weeks Diabetic, 6. 90 weeks Insulin treated Diabetic. Real Time PCR analysis was 
done using mGlu-5 specific primer and fluorescently labeled Taq probe. The TaqMan reaction mixture of 20 μl contained 25 ng 
of total RNA-derived cDNAs, 200 nM each of the forward primer, reverse primer and TaqMan probe for glutamergic- (mGlu-
5) gene, endogenous control, β-actin and 12.5 μl of TaqMan 2× Universal PCR Mastermix (Applied Biosystems). All reactions 
were performed in duplicates. The ΔΔCT method of relative quantification was used to determine the fold change in expres-
sion. This was done by first normalizing the resulting threshold cycle (CT) values of the target mRNAs to the CT values of the 
internal control β-actin in the same samples (ΔCT = CTTarget - CTβ-actin). It was further normalized with the control (ΔΔCT = 
ΔCT - CTControl). The fold change in expression was then obtained as (2-ΔΔCT) and expressed as log 2-ΔΔCT. Values are Mean ± 
S.D of 4-6 separate experiments. ***p < 0.001 when compared to control, ¶¶¶ p < 0.001 when compared to diabetic, ††† p < 
0.001 when compared to 7 weeks old diabetic, aaa p < 0.001 when compared to 7 weeks old insulin treated diabetic.
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Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Corpus striatum of Control, Diabetic and Insu- lin treated Diabetic Rats Figure 2
Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Corpus striatum of Control, 
Diabetic and Insulin treated Diabetic Rats. Sample Names. 1. 7 weeks Control, 2. 7 weeks Diabetic, 3. 7 weeks Insulin 
treated Diabetic. 4. 90 weeks Control, 5. 90 weeks Diabetic, 6. 90 weeks Insulin treated Diabetic. Values are Mean ± S.D of 4-
6 separate experiments. ***p < 0.001 when compared to control, ¶¶¶p < 0.001 when compared to diabetic, †††p < 0.001 when 
compared to 7 weeks old diabetic, aaap < 0.001 when compared to 7 weeks old insulin treated diabetic. Other details as in 
the legend to Figure-1.
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Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Brainstem of Control, Diabetic and Insulin  treated Diabetic Rats Figure 3
Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Brainstem of Control, Dia-
betic and Insulin treated Diabetic Rats. Sample Names. 1. 7 weeks Control, 2. 7 weeks Diabetic, 3. 7 weeks Insulin 
treated Diabetic. 4. 90 weeks Control, 5. 90 weeks Diabetic, 6. 90 weeks Insulin treated Diabetic. Values are Mean ± S.D of 4-
6 separate experiments. ***p < 0.001 when compared to control, ¶¶¶p < 0.001 when compared to diabetic, †††p < 0.001 when 
compared to 7 weeks old diabetic, aaap < 0.001 when compared to 7 weeks old insulin treated diabetic. Other details as in 
the legend to Figure-1.
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Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Hippocampus of Control, Diabetic and Insulin  treated Diabetic Rats Figure 4
Real-Time PCR amplification of Glutamate receptor (mGlu-5) mRNA from the Hippocampus of Control, Dia-
betic and Insulin treated Diabetic Rats. Sample Names. 1. 7 weeks Control, 2. 7 weeks Diabetic, 3. 7 weeks Insulin 
treated Diabetic. 4. 90 weeks Control, 5. 90 weeks Diabetic, 6. 90 weeks Insulin treated Diabetic. Values are Mean ± S.D of 4-
6 separate experiments. ***p < 0.001 when compared to control, ¶¶¶p < 0.001 when compared to diabetic, †††p < 0.001 when 
compared to 7 weeks old diabetic, aaap < 0.001 when compared to 7 weeks old insulin treated diabetic. Other details as in 
the legend to Figure-1.
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The isolated pancreatic islets were incubated for 4 hours at room temperature in 1 ml of RPMI medium containing 5 μM of  Ca2+ fluorescent dye, fluo 4-AM Figure 5
The isolated pancreatic islets were incubated for 4 hours at room temperature in 1 ml of RPMI medium con-
taining 5 μM of Ca2+ fluorescent dye, fluo 4-AM. The images were continuously acquired before and after addition of 10-
7 M of glutamate, at time intervals of 1.318 seconds, for a total of 600 seconds. Time series experiments were performed col-
lecting 512 × 512 pixel images at 400 Hz. Fluorescence intensity was analysed using the quantitation mode in LAS-AF software 
from Leica Microsystems, Germany. A region of interest (ROI) was drawn within a field of view. The pixel intensity was calcu-
lated for each image in the 600 seconds sequence to analyse the intracellular Ca2+ release from the pancreatic islet cells in 
experimental conditions.
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ers for L-glutamate and use L-glutamate as an intercellular
signaling molecule [71]. Both α and β-cells possess func-
tional vesicular glutamate transporters regulated by alter-
ation in glucose concentration via  the transcriptional
mechanism [72]. Maechler and Wollheim [73] recently
provided evidence that glutamate acts downstream of the
mitochondria by sensitizing the Ca2+-mediated exocytotic
process. Our studies showed that glutamate at lower con-
centration (10-7 M) increased Ca2+ release from the pan-
creatic islet cells of male Wistar rats in vitro. Also, the
stimulatory effect of glutamate on Ca2+ release was found
to be decreased at higher concentration (10-4 M). The acti-
vation of mGluR increase intracellular calcium through a
phospholipase C-inositoltriphosphate pathway [74] and
inhibits potassium currents. The resultant cytosolic Ca2+
transients serve numerous signaling functions, including
modulation of membrane excitability [75,76], synaptic
plasticity [77,78], and gene expression [79]. Glutamate
receptors regulate Ca2+-dependent secretory mechanisms
in islet cells by altering the membrane potential of these
cells. The ability of mGluR to increase intracellular Ca2+
depends on their co-expression with voltage-gated Ca2+
channels and on the ionic gradients present in the cells in
which they are expressed [80]. The metabolic changes in
islet cells reported an increase in cellular ATP that closes
ATP-sensitive potassium channels causing depolarization
of the plasma membrane potential. Subsequently, depo-
larization opens voltage-sensitive Ca2+ channels, raising
intracellular Ca2+  concentration and triggering insulin
exocytosis. The factors that modulate or disrupt IP3-
mediated Ca2+ signaling exert functional regulatory role in
physiological and pathological effects in the pancreatic
islets [81]. Thus, we conclude from our results that mGlu-
5 receptors have differential expression in brain regions of
diabetes and D+I groups as a function of age. Also, the
present study reveals the functional regulatory role of
glutamate receptors at different concentrations in intracel-
lular calcium release from pancreatic islets in vitro. In con-
clusion, the study elicits immense therapeutic
applications of glutamate receptors in memory enhance-
ment and management of degeneration in brain function
during diabetes and ageing. Also, the functional role of
glutamate receptors in calcium release has clinical signifi-
cance in insulin secretion and function.
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The isolated pancreatic islets were incubated for 4 hours at room temperature in 1 ml of RPMI medium containing 5 μM of  Ca2+ fluorescent dye, fluo 4-AM Figure 6
The isolated pancreatic islets were incubated for 4 hours at room temperature in 1 ml of RPMI medium con-
taining 5 μM of Ca2+ fluorescent dye, fluo 4-AM. The images were continuously acquired before and after addition of 10-
4 M of glutamate, at time intervals of 1.318 seconds, for a total of 600 seconds. Time series experiments were performed col-
lecting 512 × 512 pixel images at 400 Hz. Fluorescence intensity was analysed using the quantitation mode in LAS-AF software 
from Leica Microsystems, Germany. A region of interest (ROI) was drawn within a field of view. The pixel intensity was calcu-
lated for each image in the 600 seconds sequence to analyse the intracellular Ca2+ release from the pancreatic islet cells in 
experimental conditions.
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